Verastem Oncology

Today, we shared an update on our RAMP 203 trial being conducted in collaboration with Amgen to evaluate the investigational combination of avutometinib and sotorasib with or without defactinib for KRAS G12C mutant non-small cell lung cancer. Preliminary data for the triplet combination looks encouraging and we look forward to evaluating its safety and efficacy as enrollment continues. We plan to share an interim update at a medical meeting in the second half of 2025. #VerastemOnc #LungCancer #RAS Read more in our press release: https://lnkd.in/eEXaQMr6

Though his expertise is in data analytics, Bryan Ricker, who serves as our Director of Commercial Insights and Analytics, excels in uncovering key insights that drive impactful decisions and advance our mission. Inspired by our patients, Bryan’s passion fuels the important work we do every day. He consistently embodies our values through his actions, serving as an essential driver of our team’s success. Thank you, Bryan, for your consistent unwavering commitment and leadership! #VerastemOnc #EmployeeSpotlight

Our CEO Dan Paterson joined Nicole Andrews, Board Chairperson of the STAAR Low-Grade Serous Ovarian Cancer, and host Karen Jagoda on the Empowered Patient podcast to discuss Low-Grade Serous Ovarian Cancer (LGSOC) in support of education and awareness of this distinct gynecologic cancer. In partnership with STAAR Ovarian Cancer Foundation and many others, we’re raising awareness, educating the community, and paving the way for progress in this rare ovarian cancer. Listen to the full episode here: https://bit.ly/4fbdzq1  #VerastemOnc #LGSOC #LGSOCAwarenessDay #OvarianCancer

Next week we will be participating in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Dec. 3rd. A live webcast of our chat will be available on our website. Learn more: https://lnkd.in/eMhwxKdn

Today marks the 10th anniversary of #WorldPancreaticCancerDay. Over the past decade, progress has been made in understanding this often-deadly disease and researching novel treatment approaches. With more than 90% of pancreatic cancers harboring a KRAS mutation, we’re researching innovative ways to target the RAS/MAPK-pathway and other resistance mechanisms to improve outcomes for patients with pancreatic cancer. There is more work to do, and we are committed to advancing research and improving outcomes for those impacted by pancreatic cancer. Learn more about our research at https://lnkd.in/eHFgf8BS #PancreaticCancer #WPCD2024

Join us TODAY for the last Fall Online Wellness Symposium session featuring Dr. Joan Tymon-Rosario. This session aims to provide those with low-grade serous ovarian cancer (LGSOC) with the knowledge to make informed decisions about their care and quality of life. Register now: https://hubs.la/Q02YVwYs0

Cindy Jou Meyers, MBA, RAC joined Verastem as our Senior Director of Regulatory Advertising and Promotion. Cindy’s work is integral to ensuring our product marketing and communications are compliant with U.S. laws and regulations. Reflecting on her journey, Cindy shared, “𝙄 𝙟𝙤𝙞𝙣𝙚𝙙 𝙑𝙚𝙧𝙖𝙨𝙩𝙚𝙢 𝙊𝙣𝙘𝙤𝙡𝙤𝙜𝙮 𝙩𝙤 𝙝𝙚𝙡𝙥 𝙬𝙞𝙩𝙝 𝙩𝙝𝙚 𝙣𝙤𝙗𝙡𝙚 𝙢𝙞𝙨𝙨𝙞𝙤𝙣 𝙤𝙛 𝙢𝙖𝙠𝙞𝙣𝙜 𝙨𝙪𝙧𝙚 𝙥𝙖𝙩𝙞𝙚𝙣𝙩𝙨 𝙬𝙞𝙩𝙝 𝙘𝙖𝙣𝙘𝙚𝙧 𝙙𝙤𝙣'𝙩 𝙧𝙪𝙣 𝙤𝙪𝙩 𝙤𝙛 𝙤𝙥𝙩𝙞𝙤𝙣𝙨. 𝙄 𝙬𝙖𝙣𝙩𝙚𝙙 𝙩𝙤 𝙬𝙤𝙧𝙠 𝙞𝙣 𝙩𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘 𝙖𝙧𝙚𝙖𝙨 𝙬𝙞𝙩𝙝 𝙝𝙞𝙜𝙝 𝙪𝙣𝙢𝙚𝙩 𝙣𝙚𝙚𝙙 𝙖𝙣𝙙 𝙬𝙝𝙚𝙧𝙚 𝙤𝙪𝙧 𝙥𝙧𝙤𝙙𝙪𝙘𝙩𝙨, 𝙞𝙛 𝙖𝙥𝙥𝙧𝙤𝙫𝙚𝙙 𝙗𝙮 𝙩𝙝𝙚 𝙁𝘿𝘼, 𝙘𝙤𝙪𝙡𝙙 𝙢𝙖𝙠𝙚 𝙖 𝙢𝙚𝙖𝙣𝙞𝙣𝙜𝙛𝙪𝙡 𝙙𝙞𝙛𝙛𝙚𝙧𝙚𝙣𝙘𝙚 𝙞𝙣 𝙩𝙝𝙚 𝙡𝙞𝙫𝙚𝙨 𝙤𝙛 𝙥𝙖𝙩𝙞𝙚𝙣𝙩𝙨.” We’re thrilled to have Cindy on board, bringing her expertise and passion to our mission of advancing treatment options for patients with cancer.    #VerastemOnc #EmployeeSpotlight

#Pancreaticcancer may cause only vague symptoms that could be confused with many other abdominal or gastrointestinal issues. 🔍💜 It’s important to listen to your body and talk to your doctor about pancreatic cancer if you experience any of these warning signs. 🗂 SAVE this post to refer back to, 💌 SEND it to your loved ones and ➡️ VISIT pancan.org/awareness to learn more about the symptoms of this disease. #PanCANawareness

Today, we’re reporting our Q3 financial results and recent business progress, including completing our rolling NDA submission of our investigational combination of avutometinib plus defactinib for patients with recurrent KRAS mutant LGSOC. With a potential FDA approval next year, we’re also continuing our U.S. commercial launch preparations targeted for mid-2025. As we look ahead to the rest of the fourth quarter, we’re are working on advancing programs in our pipeline, including preparing a U.S. IND application for VS-7375/GFH375, an oral KRAS G12D (ON/OFF) inhibitor. #VerastemOnc #LGSOC #FDA #G12D https://lnkd.in/e9GHYP5G

It is a common misconception that only people who smoke get lung cancer. It is estimated that 65% of new lung cancer diagnoses occur in people who have no smoking history or are former smokers. We need your help this #LungCancerAwarenessMonth to share the facts with your community. Let friends and family know #AnyoneWithLungs can get lung cancer. Get started by visiting lungevity.org/lcam to spread awareness throughout November. #LCAM #lcsm #lungcancer #transforminglungcancer